A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

Completed · Phase 1

Conditions studied: Malignancies Multiple

In brief

Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.

Key facts

Study ID

NCT03346837

Run by

Bristol-Myers Squibb

People needed

53

Starts

2017-11-22

Expected to finish

2017-12-20

Last updated by the study team

2018-02-28

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body mass index 18.0 to 32.0 kg/m2, inclusive
• Must have normal renal function demonstrated by GFR, calculated by Chronic Kidney Disease Epidemiology Collaboration formula
• Women must not be of childbearing potential (cannot become pregnant)

You may not qualify if…

• Any significant acute or chronic medical illness
• History of glucose-6-phosphodiesterase (G6PD) deficiency
• Personal or family history of cytochrome b5 reductase deficiency
• Other protocol defined inclusion / exclusion criteria could apply

Where it is running

• PPD — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.